Skip Navigation

Clinical Studies

Canine Neurology

Evaluation of a New Drug (Rapamycin) in Dogs with Disk Herniation

Title

Evaluation of a New Drug (Rapamycin) in Dogs with Disk Herniation

Contact Person

Elizabeth Scanlin, BS
Alisha Selix
Juan Torres, BS, LVT
Julie Harris, AAS, LVT
Jonathan M. Levine, DVM, DACVIM-Neurology

Species

Dogs

Inclusion Criteria and General Background Information

  • T3-L6 spinal cord injury due to disk herniation
  • Systemically healthy otherwise based on PE and bloodwork
  • No breed restrictions
  • No gender restrictions
  • No weight limit
  • Inability to walk for a period not exceeding 48 hours prior to enrollment
  • Surgical treatment elected based on CT or MRI

Exclusion Criteria

  • Widespread cancer or inflammation
  • History of breeding/pregnancy (within the last 6 months)
  • Presence of significant multi-organ damage
  • Estimated life expectancy of <2 weeks
  • Unsuitable temperament for evaluations required in this study

Owner Commitments

Each enrolled animal will participate for a total of 90 days (3 months). Participating dogs will be hospitalized for seven days after surgery (Days 1-7), and then return to Texas A&M on days 42 and 90 following surgery, for recheck evaluations that will each last approximately 4 hours. Further details on study procedures can be obtained by contacting the Neurology staff at 979-845-2351

Financial Incentives

There are no financial obligations by the owner to Texas A&M University for participation in this study, although you will be responsible for standard fees associated with initial examination, surgery and recovery. The 42 day and 90 day follow-up visits will be paid for by the investigator and are required for participation.  A $500 discount will be paid to the clients after completion of the day 90 follow-up visit.

 

US Department of Defense Canine Spinal Cord Injury Study: Part 2

Download Brochure

Title US Department of Defense Canine Spinal Cord Injury Study: Part 2
Contact Person

Alisha Selix
Elizabeth Scanlin, BS
Julie Harris, AS, LVT
Juan Torres, BS, LVT
Jonathan M. Levine, DVM, DACVIM-Neurology

Species Dog
Inclusion Criteria and General Background Information
  1. Dogs must have ≤ 2 day history of spinal cord dysfunction resulting in a loss of coordination in the back legs
  2. The spinal cord injury must be suspected to be due to disk herniation and must be located between the T3 and L3 vertebrae
  3. Dogs must be male or male castrated and weigh between 7-35 pounds
  4. Dogs must be an appropriate candidate for surgery
Exclusion Criteria Dogs receiving steroids within 7 days of injury cannot participate.
Owner Commitments Animals will participate during the normal course of their hospitalization, for the diagnosis and treatment of disk herniation. Dogs will receive either placebo or study drug one time. Dogs will have urinary function and limb movements measured at various time points during their hospitalization and at a 42 day re-check point. Further details on study procedures can be obtained by contacting the neurology staff at 979-845-2351
Financial Incentives

There are no financial obligations by the owner to Texas A&M University for participation in this study, although they will be responsible for standard fees associated with initial examination, surgery and recovery. The standard 4-6 week follow-up visit will be paid for by the investigator and is required for participation.

Participation in the study with successful completion of all visits will result in a final client cost of $1200 for all procedures. Animals failing to complete the study may be subject to the entire cost of procedures (approximately $3500).

US Department of Defense Canine Spinal Cord Injury Study: Part 1

Download Flyer

Title: US Department of Defense Canine Spinal Cord Injury Study: Part 1
Contact Person:

Alisha Selix
Elizabeth Scanlin, BS
Julie Harris, AS, LVT
Juan Torres, BS, LVT
Jonathan M. Levine, DVM, DACVIM-Neurology

Species: Dog
Inclusion Criteria and General Background Information:
  1. Dogs must have ≤ 2 day history of spinal cord dysfunction resulting in a loss of coordination in the back legs
  2. The spinal cord injury must be suspected to be due to disk herniation.
  3. Dogs must be male or male castrated and weigh between 7-35 pounds.
Exclusion Criteria: Dogs lacking pain perception in the back legs cannot be enrolled.
Owner Commitments: Animals will participate during the normal course of their hospitalization, for the diagnosis and treatment of disk herniation. Dogs will have urinary function measured at various time points during their hospitalization and at a 42 day re-check point. Further details on study procedures can be obtained by contacting the neurology staff at 979-845-2351
Financial Incentives:

There are no financial obligations by the owner to Texas A&M University for participation in this study, although they will be responsible for standard fees associated with initial examination, surgery and recovery. A 4-6 week follow-up visit will be paid for by the investigator and is required for participation.

Participation in the study with successful completion of all visits will result in a cost for all procedures (spinal imaging, spinal surgery, rehabilitation, 7 days of hospitalization) of $3000, which is $500 less than our standard fee for back surgery.

 

Spinal Cord Injury Study: Correlation of MRI to Functional Outcome

Title: Spinal Cord Injury Study: Correlation of MRI to Functional Outcome
Contact Person:

Elizabeth Scanlin, BS
Alisha Selix
Julie Harris, AS, LVT
Juan Torres, BS, LVT
John F. Griffin IV, DVM, DACVR
Jonathan M. Levine, DVM, DACVIM-Neurology

Species: Dogs
Inclusion Criteria and General Background Information:
  1. Dogs must have ≤ 7 day history of spinal cord dysfunction resulting in a loss of coordination in the back legs
  2. The spinal cord injury must be suspected to be due to disk herniation.
  3. Dogs must weigh between 6-33 pounds.
Exclusion Criteria: None
Owner Commitments: Animals will participate during the normal course of their hospitalization, for the diagnosis and treatment of disk herniation. Dogs will have a special MRI that takes about 70 minutes, instead of the typical 20-30 minutes. Dogs will be given MRI contrast medium (gadolinium). Further details on study procedures can be obtained by contacting the neurology staff at 979-845-2351
Financial Incentives: There are no financial obligations by the owner to Texas A&M University for participation in this study, although they will be responsible for standard fees associated with initial examination, surgery and recovery. A 4-6 week follow-up visit will be paid for by the investigator and is required for participation.

Participation in the study with successful completion of all visits will result in a cost for all procedures (spinal imaging, spinal surgery, rehabilitation, 7 days of hospitalization) of $3000, which is $500 less than our standard fee for back surgery.

Canine Oncology

Canine Study 1: Activated autologous T cell killing of CD 20+ B cell lymphoma in the Dog.

Title:

Activated autologous T cell killing of CD 20+ B cell lymphoma in the Dog.

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology)
Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Any dog weighing over 35 lbs that has been diagnosed with B cell Lymphoma and is being treated with prednisone alone.

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study. Dogs receiving other therapies including chemotherapy or radiation therapy (other than prednisone) are not eligible for this study. Dogs with T cell lymphoma are not eligible for this study.

Owner Commitments:

Dogs will have an initial blood draw to isolate T cells from the blood. 6 weeks later, three infusion will begin. These will be given every other week for a total of 6 weeks. A blood sample collection will be necessary for the off weeks. 7-10 days after completion of therapy a biopsy of one lymph node and blood work will be collected. Animals will be sedated or anesthetized for the sample collection. Blood sample collections and physical exams will occur monthly thereafter.

Financial Incentives:

Immunophenotyping (determination of the type of lymphoma using special stains) will be done free of charge for all dogs with Lymphoma entering the study. The manufacturing of the T cell infusion and visit costs associated with these infusions will be paid for by the study.
This study is currently open.

Canine Study 2: Alteration of the intestinal microflora after chemotherapy in dogs.

Title:

Alteration of the intestinal microflora after chemotherapy in dogs.

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology)
Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Your dog must have a confirmed diagnosis of cancer and receive doxorubicin (a chemotherapy drug) as part of their treatment protocol. Two pretreatment fecal (stool) samples are needed and may be frozen before your first appointment.

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study. Dogs receiving probiotics of any type (e.g. Fortiflora ®) will be excluded. Dogs with significant pre-existing intestinal disease will also be excluded.

Owner Commitments:

You will be required to collect and bring in (or send in by mail) two pretreatment fecal samples as well as collect fecal sample the week before and 72 hours after doxorubicin chemotherapy. Blood will also be drawn at the first visit and possibly at subsequent visits for evaluation of B vitamin levels.

Financial Incentives:

All costs associated with this study will be provided as part of your participation. After entering the study fecal collection tubes will be provided and shipping for any samples will be paid. Costs associated with diagnosis, staging and doxorubicin therapy will be the responsibility of the owner.
This study is currently open. Owners Will receive a $150 credit after each round of the study. A total of $300 can be earned after study completion.

Canine Study 3: S100b inhibitors for the treatment of canine malignant melanoma

Title:

S100b inhibitors for the treatment of canine malignant melanoma

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology)
Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Your dog must have a confirmed diagnosis of melanoma and several tests to ensure his/her general health and to assess how advanced the disease is prior to treatment. The tumor will be biopsied prior to therapy. Tumors must be large enough to biopsy and your dog must have no other significant health problems.

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study. Dogs cannot be receiving concurrent chemotherapy (including corticosteroids) or radiation therapy. Dogs must be off of all such therapy for 3 weeks prior to study enrollment. No dogs under 15 kg (<33 lbs) will be allowed in this study.

Owner Commitments:

Prior to entry into this study, your dog must have a confirmed diagnosis of melanoma and staging tests to ensure his/her general health and to assess how advanced the disease is. The tumor will need to be biopsied before therapy for this purpose. Your dog will receive one of two drugs or a combination of the two. Both drugs are FDA approved and have been used in dogs previously for other reasons. Interactions between these drugs and other drugs are unknown; therefore it is important to tell your veterinarian about any medications (and supplements) your dog is currently taking. It is strongly encouraged to eliminate all unnecessary medications. This should be discussed with your oncologist if you have any questions.

Financial Incentives:

All costs associated with this study will be provided as part of your participation. In the event any complications arise during the twenty-nine (29) day study period (time period between drug administration and assessment), their management will be covered by study funds up to $750/dog. This would include any unanticipated hospitalizations. However, all costs exceeding $750/dog are your responsibility.
This trial is currently open!

Canine Study 4: Radiation Therapy for dogs with multicentric lymphoma

Title:

Radiation Therapy for dogs with multicentric lymphoma

Contact Person:

Michael Deveau, MS, DVM, DAVR(Radiation Oncology)
Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Any dog weighing over 10 lbs that has been newly diagnosed with lymphoma.

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study. Dogs receiving other therapies including chemotherapy or radiation therapy (other than prednisone) are not eligible for this study.

Owner Commitments:

Dogs will receive full body imaging before therapy, then treated with chemotherapy for 19 weeks (standard therapy for canine lymphoma), after completion of chemotherapy dogs will receive 2 weeks (10 doses, M-F) of radiation therapy.

Financial Incentives:

The costs of the imaging associated with the study as well as some of the staging costs, radiation therapy costs, anesthesia costs and some blood work costs will be covered by this study. The cost of chemotherapy will be the responsibility of the owner.
This study is currently open!

Canine Study 5: Evaluation of new renal (kidney) biomarkers for kidney damage in normal dogs and dogs receiving nephrotoxic drugs.

Title:

Evaluation of new renal (kidney) biomarkers for kidney damage in normal dogs and dogs receiving nephrotoxic drugs.

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Dogs receiving kidney toxic drugs (e.g., tyrosine kinase inhibitors):

  • Must be at least 2 years old
  • Must weigh at least 22 lbs
  • Must have no previous history of kidney disease or protein in the urine
  • Must have a life expectancy of at least 4 months

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study. Dogs with kidney disease, current urinary tract infections or protein in the urine are also excluded from this study.

Owner Commitments:

Dogs receiving Kidney toxic drugs (e.g., tyrosine kinase inhibitors) will participate for up to 6 months with a pretreatment blood and urine sample, and additional samples two weeks after initiation of therapy and then monthly thereafter.

Financial Incentives:

All laboratory tests associated with kidney panel will be covered by the study. Any additional costs or therapies will be the responsibility of the owner.
This trial is currently open!

Canine Study 6: Evaluation of a new therapy for dogs with any type of naive or first relapsed lymphoma.

Title:

Evaluation of a new therapy for dogs with any type of naive lymphoma.

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Dogs with any stage or type of lymphoma qualify as long as they feel ok and have not received any prior treatments for at least 2 weeks prior to study initiation. Dogs must weigh at least 10 lbs and be able to travel to TAMU weekly for 13 consecutive weeks.

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study.

Owner Commitments:

Owners will be required to travel to TAMU weekly for 13 consecutive weeks. The first appointment is likely to take most of the business day; however, additional appointments will likely take 2-4 hours.

Financial Incentives:

All costs and fees associated with the trial are covered. Additionally some of the staging costs will also be covered during the first visit if the dog is eligible. There is also a $750 fund to cover any side effects during the trial period. Any costs that exceed the side effects funds will be the responsibility of the owner.
This trial is currently open!

Canine Study 7: Evaluation of a new therapy, Leukothera, for the treatment of canine hematopoietic tumors (lymphoma, leukemia and multiple myeloma).

Title:

Evaluation of a new therapy, Leukothera, for the treatment of canine hematopoietic tumors (lymphoma, leukemia and multiple myeloma).

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Dogs with a newly diagnosed or first relapse of any hematopoietic tumor (lymphoma, multiple myeloma or leukemia) with systemic disease (at least a stage III lymphoma) are eligible to enroll. Dogs must weigh at least 10 kg (22 lbs).

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study.

Owner Commitments:

Dogs will be required to visit TAMU weekly for 5 weeks for treatment and therapy. The initial visit costs are not covered by the study as we determine if your dog is eligible; however, once enrolled, all fees associated with the study will be covered. Dogs will be required to come on the same day each week for approximately 3 hours each visit to be examined, run blood work and administer therapy.

Financial Incentives:

All costs associated with therapy after enrollment are covered by the study. There is an additional $750 to help with any possible side effects your dog may experience. Any costs beyond $750 for side effects will be the responsibility of the owner.
This trial is currently open and enrolling

Canine Study 8: Evaluation of a new therapy for dogs with Grade II or Grade III mast cell tumors (with visible tumors) that have not received any chemotherapy or radiation therapy with the exception of corticosteroids. Dogs who have previously had surgery but now have recurrence will qualify.

Title:

Evaluation of a new therapy for dogs with Grade II or Grade III mast cell tumors (with visible tumors) that have not received any chemotherapy or radiation therapy with the exception of corticosteroids. Dogs who have previously had surgery but now have recurrence will qualify.

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Dogs with any visible mast cell tumor (grade II or III) may enroll as long as they feel ok and have not received any prior treatments besides corticosteroids. Dogs must weigh at least 10 lbs and be able to travel to TAMU weekly for 13 consecutive weeks.

Exclusion Criteria:

Dogs with significant concurrent disease are excluded from this study.

Owner Commitments:

Owners will be required to travel to TAMU weekly for 13 consecutive weeks. The first appointment is likely to take most of the business day; however, additional appointments will likely take 2-4 hours.

Financial Incentives:

All costs and fees associated with the trial are covered. Additionally some of the staging costs will also be covered during the first visit if the dog is eligible. There is also a $750 fund to cover any side effects during the trial period. Any costs that exceed the side effects funds will be the responsibility of the owner.
This trial is currently open!

Canine Trial 9: Evaluation of biomarkers as risk factors for lymphoma in Golden Retrievers.

Title:

Evaluation of biomarkers as risk factors for lymphoma in Golden Retrievers.

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Any golden retriever with lymphoma may qualify for this trial.

Exclusion Criteria:

Dogs without lymphoma or with other tumors may not qualify for this trial.

Owner Commitments:

Dogs will participate with a cheek swab on a one time bases. Participation in this trial is expected to add no more than 30 minutes to the total visit time.

Financial Incentives:

There is no cost for participation in this trial. There are no financial benefits for participation in this trial.
This trial is currently open!

Canine Trial 10: Evaluation of DNA methylation patterns as risk factors for lymphoma in Golden Retrievers.

Title:

Evaluation of DNA methylation patterns as risk factors for lymphoma in Golden Retrievers.

Contact Person:

Heather Wilson, DVM, DACVIM (Oncology) Clinic Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines

Inclusion Criteria and General Background Information:

Any golden retriever with B cell lymphoma may qualify for this trial.

Exclusion Criteria:

Dogs without lymphoma or with other tumors may not qualify for this trial.

Owner Commitments:

Dogs will participate with a cheek swab on a one time bases. Participation may include a biopsy of the lymph node, a fine needle aspirate of the lymph node and a blood sample. Participation may add 1-2 hours to the visit.

Financial Incentives:

There is no cost for participation in this trial. There are no financial benefits for participation in this trial.
This trial is currently open!

 

Canine/Feline Study 11:

Title:

Pilot Study of AuroLase® Therapy for the Treatment of Solid Tumors in Canine and Feline Patients

Contact Person:

Micheal Deveau, DVM, MS, DACVR (Radiation Oncology) Phone: 979-845-2351
Email: oncology@cvm.tamu.edu

Species:

Canines and Felines

Inclusion Criteria and General Background Information:

Any treatment naïve, recurrent, and/or refractor dog with a confirmed diagnosis or a soft tissue sarcoma or squamous cells carcinoma limited to the head and neck, oral cavity, or limb is eligible for enrollment. Any cat with a confirmed diagnosis or an oral squamous cell carcinoma that has not received treatment, has recurrent disease, or has not responded to treatment is eligible for enrollment.

Exclusion Criteria:

Dogs and cats with significant concurrent disease are excluded from this study. Poor candidates for anesthesia are excluded.

Owner Commitments:

The AuroLase® therapy will take place over two consecutive days at TAMU. Treatment on day one will take approximately 60 minutes and treatment on day two will take approximately 90 minutes. Study patients will be returned to their owners between day one and two, and at the end of the day on day 2. The study requires routine follow up visits starting two weeks after treatment and then once a month for 3 months. Follow up visits will take approximately 60 minutes.

Financial Incentives:

Owners are responsible for costs associated with diagnostics, staging, and other complimentary treatments, and any potential complications not associated directly with AuroLase® Therapy. There are no other financial obligations by the owner to TAMU for participation in this study.
This trial is currently open and enrolling